Randox Food Diagnostics has entered one of the world’s key honey markets this quarter, delivering its leading drug-residue screening technology to Balarisi Honey, Turkey. The deal is a major development for the company as it breaks into the world’s second largest honey market.
As well as floral products, Balarisi specialises in niche varieties such as chestnut honey and pine honey, ranking within the top three processors in this region. The deal will see Balarisi screen across Randox Food Diagnostics main Antimicrobial products AM I, II, III, & IV.
Developed through a decade of research and development with an investment of £200m, Biochip Array Technology can detect multiple drug residues from a single honey sample, adding huge potential for savings via time and cost. Marked by quality and ease of sample preparation, screening with the Evidence Investigator allows processors such as Balarisi to demonstrate compliance with regulations covering the use of antibiotics within honey production.
An indication of the growing reputation of multiplex technology, the sales process was both rapid and straightforward. Randox Food Diagnostics Honey business development manager Aaron Tohill explained, “From initial contact in May, we had a couple of meetings before Balarisi engaged with one of our reference laboratories. The feedback was very positive and the installation was completed in June. The Evidence Investigator is increasingly renowned for its accuracy (non-compliant samples < 5%) and reliability and with this initial success we would hope to further develop our presence in the Turkish market.”
